Blog

The infusion chair is losing to the kitchen table. In the Global Autoinjectors Market Size, Share, Trends & Forecast 2020–2035 report, home and self-care settings account for about 68% of autoinjector revenue in 2025 and reach USD 33,752.72 Million by 2035 at a 13.89% CAGR. Two forces are pushing therapy out of the clinic: a biosimilar wave that multiplies device presentations without new-molecule risk, and the conversion of intravenous biologics, including cancer immunotherapy, to subcutaneous injection.

Why biologics belong in an autoinjector

Under FDA combination-product regulation, the device and the antibody are approved as one unit, and the report quantifies ten antibody classes delivered that way: TNF-targeting, interleukin- and interleukin-receptor-targeting, IgE-targeting, CTLA-4 fusion proteins, BAFF-targeting, CGRP-targeting, PCSK9-targeting, integrin-targeting and others. Randomised crossover trials cited in the report consistently show patients preferring autoinjectors to prefilled syringes, which is what makes unsupervised home use viable. The WHO expects the population aged 60 and over to double to 2.1 billion by 2050, and GBD 2021 projects rheumatoid arthritis prevalence to grow 80.2% to 31.7 million by 2050 — the two cohorts most likely to be on a self-injected biologic.

Wave one: biosimilars multiply the device base

The FDA biosimilars programme has now approved 90 products, and the Purple Book shows interchangeability increasingly granted at the level of the individual autoinjector presentation, which means a biosimilar competes on device experience as much as on price. The report's dedicated biosimilar chapter profiles Celltrion, Samsung Bioepis, Fresenius Kabi, Viatris, Lupin, Sun Pharmaceutical, Zydus Lifesciences, Aurobindo, Baxter and Amneal, and its price-analysis chapter models biosimilar price erosion against each modality's revenue line. For device makers, every biosimilar launch is a new platform qualification without new clinical risk.

Wave two: IV to subcutaneous, now including oncology

The first subcutaneous PD-1 inhibitors and the approval of KEYTRUDA QLEX (Merck) pull cancer immunotherapy onto injector-compatible formats. That conversion needs large volumes and high viscosities that spring-driven 1 mL devices cannot deliver, which is why the fastest-growing container capacity in the report is over 2.25 mL at 14.67% CAGR. Platforms built for it include Enable Injections enFuse on-body delivery, SHL Medical Maggie 5.0, the 5.5 mL BD/Ypsomed system and 5–20 mL on-body cartridges referenced in the report's bull case, and the Gerresheimer / Portal PRIME Nexus electromechanical device tested to 600 cP.

The recent launches that show the direction

• FDA approved the AstraZeneca Saphnelo Pen for once-weekly self-administration in systemic lupus erythematosus (April 2026).
• Haselmeier PiccoJect, a two-step 1 mL / 2.25 mL autoinjector, entered clinical trials (July 2026).
• UCB's Bimzelx autoinjector presentations extend IL-17 therapy to home use.
• embecta acquired Owen Mumford with up to £50 million tied to Aidaptus autoinjector sales — a bet on the prefilled-syringe-based platform that still holds ~89% of revenue.

The human-factors bill comes with the move home

Self-injection puts usability at the centre of safety. The report analyses FDA human-factors engineering guidance and ISO 11608 requirements, the FDA and MHRA recalls of devices that failed to activate or needed excess activation force, and the needle anxiety that suppresses uptake in otherwise eligible patients. It treats use-error mitigation, training and connected adherence support as competitive differentiators, not compliance costs, and quantifies caregiver, family-member and healthcare-professional administration separately from patient self-administration so pharma partners can size each channel.

All market figures in this article are from the Global Data Route Analytics report Global Autoinjectors Market Size, Share, Trends & Forecast 2020–2035. External links open in a new tab and lead to the regulator, company or database sources cited in the report.